UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,

OMB APPROVAL

OMB Number: 3235-0076
Expires: April 30, 2008
Estimated average burden
how

Pret 07049551

DATE RECEIVED

Name of Offering ([] check if this is an ame	ndment and name has changed,	, and indicate ch	ange.)					
Oraya Therapeutics, Inc., Series A Prefer	red Stock Financing		<u> </u>		<u> </u>			
Filing Under (Check box(es) that apply):	[.] Rule 504] Rule 505	[X] Rule 506	[]Section 4(6)	ULOE			
Type of Filing: [X] New Filing	Amendment	<u> </u>						
	A. BASIC IDEN	rification !	DATA	RECDET				
1. Enter the information requested about	<u> </u>		·	MADO	- 1			
Name of Issuer ([] check if this is an amend	iment and name has changed, a	and indicate char	nge.)	1 : : : : : : : : : : : : : : : : : : :	007			
Oraya Therapeutics, Inc.								
Address of Executive Offices								
1455 Adams Drive, Suite 2005, Menlo Pa	rk, CA 94025	·	650.265.4058		08 ₆ /			
Address of Principal Business Operations	(Number and Street, City, Sta	te, Zip Code)	Telephone Number (I					
(if different from Executive Offices)	•		AACCED					
	· · ·	DK	OCESSED	<u> </u>				
Brief Description of Business		# 5.7						
Medical devices and related technology				<u> </u>				
Type of Business Organization		- <u>. </u>	APR 0 6 2007 /					
[X] corporation	[] limited partnership, a	already formed		[] other (please specif	ỳ):			
[] business trust	[] limited partnership, t	o be formed	THOMSON -					
Actual or Estimated Date of Incorporation or Jurisdiction of Incorporation or Organization		[200	U CINIANCIAL] Estimated			
<u> </u>	CN for Canada; FN	•			DE]			

SECTION 4(6), AND/OR

UNIFORM LIMITED OFFERING EXEMPTION

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

A. BASIC IDENTIFICATION DATA

- 2. Enter the information requested for the following:
 - Each promoter of the issuer, if the issuer has been organized within the past five years;
 - Each beneficial owner having the power to vote or dispose, or direct the vote or disposition, of, 10% or more of a class of equity securities
 of the issuer;
 - Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
 - Each general and managing partner of partnership issuers.

Check Box(es) that Apply:	[] Promoter [X] Beneficial Owner	[X] Executive Officer	[X] Director	
	[] General and/or Managing Partner		. <u></u>	
Full Name (Last name first, if in Gertner, Michael E.	dividual)	·		
	(Number and Street, City, State, Zip Code)		•	
Check Box(es) that Apply:	Promoter Beneficial Owner	[] Executive Officer	[X] Director	
	[] General and/or Managing Partner	[] Executive Officer	[A] Director	<u>. </u>
Full Name (Last name first, if in Neels, Guido J.	dividual)			
	(Number and Street, City, State, Zip Code)			
1455 Adams Drive, Suite 2005		•		
Check Box(es) that Apply:	[] Promoter [] Beneficial Owner [] General and/or Managing Partner	[X] Executive Officer	[] Director	
Full Name (Last name first, if in	dividual)			
Cohn, Peter				
Business or Residence Address (1020 Marsh Road, Menlo Parl	(Number and Street, City, State, Zip Code)	•		
Check Box(es) that Apply:	Promoter [X] Beneficial Owner	[] Executive Officer	[] Director	
Check Box(es) that Apply.	General and/or Managing Partner	[] Executive Officer	[] Director	
Full Name (Last name first, if in				
Essex Woodlands Health Vent	ures Fund VI, L.P.			
Business or Residence Address ((Number and Street, City, State, Zip Code)			
435 Tasso Street, Suite 305, Pa		<u> </u>		
Check Box(es) that Apply:	[] Promoter [X] Beneficial Owner [] General and/or Managing Partner	[] Executive Officer	[] Director	
Full Name (Last name first, if in				
Essex Woodlands Health Vent	ures Fund VII, L.P.		• • •	
Business or Residence Address (435 Tasso Street, Suite 305, Pa	(Number and Street, City, State, Zip Code)			
Check Box(es) that Apply:	[] Promoter [] Beneficial Owner	[] Executive Officer	{ } Director	
	[] General and/or Managing Partner		· · · · · · · · · · · · · · · · · · ·	
Full Name (Last name first, if in	dividual)	•		
Business or Residence Address	(Number and Street, City, State, Zip Code)			
Check Box(es) that Apply:	[] Promoter [] Beneficial Owner	[] Executive Officer	[] Director	
Full Name (Last name first, if in	[] General and/or Managing Partner	<u> </u>		
run Name (Last name mst n m	dividual)			
Business or Residence Address	(Number and Street, City, State, Zip Code)			
Check Box(es) that Apply:	[] Promoter [] Beneficial Owner [] General and/or Managing Partner	[] Executive Officer	[] Director	
Full Name (Last name first, if in				
Business or Residence Address	(Number and Street, City, State, Zip Code)			
Check Box(es) that Apply:	[] Promoter [] Beneficial Owner [] General and/or Managing Partner	[] Executive Officer	[] Director	•
Full Name (Last name first, if in			· · · · · · · · · · · · · · · · · · ·	
Business or Residence Address	(Number and Street, City, State, Zip Code)	· · · · · · · · · · · · · · · · · · ·		
	, , , , , , , , , , , , , , , , , , ,	<u> </u>		
	(Use blank sheet, or copy and use additional copie	s of this sheet, as necessary.)		

•	•			B	. INFO	RMAT	ION A	BOUT (OFFER	ING					
١.	Has the issue	r sold, or o	does the iss	suer intend	to sell, to	non-accrec	lited inves	tors in this nn 2, if fili	offering? ng under l	JLOE.			**********	Yes { }	No [X]
2.	What is the n	ninimum i	nvestment	that will b	e accepted	from any	individual'	?	•••••	*************		******************	,	\$ <u>NO</u>	NE
3.	Does the offe	ering perm	, it joint ow	nership of	a single ur	nit?	•••••••				***************************************	************	••••••	Yes []	No [X]
4.	Enter the information agent of a brobe listed are	n for solici oker or de	tation of p aler registe	urchasers i red with th	in connect he SEC an	ion with sa d/or with a	iles of secu	orities in th tates, list th	e offering. ne name of	If a person the broker	on to be lis or dealer	sted is an a . If more t	ssociated	perso	
Full	Name (Last n	ame first,	if individu	al)		- ,		 .		·					
Bus	iness or Resid	ence Addr	ess (Numb	er and Stre	et, City, S	tate, Zip C	ode)								
Nar	ne of Associat	ed Broker	or Dealer									·,			
Stat	tes in Which P	erson Liste	d Has Soli	icited or In	tends to S	olicit Purch	nasers		, .						
												1			
			s" or check						*					All Sta	tes
	{AL} [IL] [MT] [RII	[AK] [IN] [NE] [SC]	[AZ] [IA] [NV] [SD]	[AR] [KS] [NH] [TN]	{CA} [KY] [NJ] [TX]	[CO] [LA] [NM] [UT]	[CT] [ME] [NY] [VT]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	(FL) MI) [OH] (WV)	[GA] [MN] [OK] [WI]	[HI] MS] [OR] [WY]	[ID] [MO] [PA] [PR]		
Ful	l Name (Last n					1911	<u> </u>	1.4.41	1223		1,,,,1	_1" '1_			
Bus	siness or Resid	ence Addr	ess (Numb	er and Stre	et, City, S	tate, Zip C	lode)	 ,							
Nar	ne of Associat	ed Broker	or Dealer						:						
Stat	tes in Which P	erson Liste	ed Has Sol	icited or In	tends to S	olicit Purcl	hasers		· · · · · ·				•		
	(Check	"All State	s" or check	k individus	d States)		·		***************************************				{ } #	All Sta	tes
	[AL] [IL] [MT] [RI]	[AK] [IN] [NE] [SC]	[AZ] [IA] [NV] [SD]	(AR] (KS) [NH] [TN]	[CA] [KY] [NJ] [TX]	[CO] [LA] [NM] [UT]	[CT] [ME] [NY] [VT]	[DE] [MD] [NC] [VA]	[DC] [MÄ] [ND] [WA]	[FL] [MI] [OH] [WV]	[GA] [MN] [OK] [WI]	[HI] [MS] [OR] [WY]	[ID] [MO] [PA] [PR]		
Ful	l Name (Last n	ame first,	if individu	al)		•									
Bus	siness or Resid	ence Addr	ess (Numb	er and Str	eet, City, S	state, Zip C	ode)		·				-		
Nar	me of Associat	ed Broker	or Dealer												
Sta	tes in Which P	erson Liste	ed Has Sol	icited or In	tends to S	olicit Purcl	hasers	<u>-</u>							
	(Check	"All State	s" or checl	k individua	d States)	************	***********						[]	All Sta	tes
	(AL) [IL) {MT] [RI]	[AK] [IN] [NE] [SC]	(AZ) [IA] [NV] [SD]	[AR] [KS] [NH] [TN]	(CA) (KY) [NJ] [TX]	[CO] [LA] [NM] [UT]	(CT] [ME] [NY] [VT]	[DE] [MD] [NC] [VA]	(DC) [MA] . [ND] [WA]	(FL) [MI] [OH] [WV]	[GA] [MN] [OK] [WI]	(HI] [MS] [OR] [WY]	(ID] [MO] [PA] _[PR]		

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS 1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box [] and indicate in the columns below the amounts of the securities offered for exchange and already exchanged. Type of Security Aggregate Amount Already Offering Price Sold Debt..... \$4,000,000.00 \$4,000,000.00 Equity [] Common [X] Preferred Convertible Securities (including warrants)..... Partnership Interests Other (Convertible Promissory Notes)..... Total \$4,000,000.00 \$4,000,000.00 Answer also in Appendix, Column 3, if filing Under ULOE 2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." Number Aggregate Dollar Amount Investors of Purchases Accredited Investors.... Non-accredited Investors. Total (for filings Under Rule 504 Only)..... Answer also in Appendix, Column 4 if filing under ULOE 3. If this filing is for an offering Under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1. Type of Security Type of Dollar Amount Sold Security Rule 505 Regulation A Rule 504 a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate...

Accounting Fees []
Engineering Fees []
Sales Commissions (Specify finder's fees separately) []
Other Expenses (identify): []
Total [X]

\$20,000

\$20,000

b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." \$3,980,000.00 Indicate below the amount of the adjusted gross proceeds to the issuer used or 5. proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above. Payments to Officers, Directors, & Affiliates Payments To Others Salaries and fees..... Research and Development..... Purchase, rental or leasing and installation of machinery and equipment Construction or leasing of plant buildings and facilities [] Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets of securities of another Repayment of indebtedness...... Working capital and general corporate purposes \$3,980,000.00 Other (specify): []

· [X]

\$3,980,000.00

Column totals

Total payments listed (column totals added)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

D. FEDERA	L SIGNATURE
The issuer has duly caused this notice to be signed by the undersigned duly auth constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exc the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 50	change Commission, upon written request of its staff, the information furnished by
Issuer (Print or Type) Oraya Therapeutics, Inc.	Signature Date 03/22/07
Name of Signer (Print or Type) Peter Cohn	Title of Signer (Print or Type) Secretary

Attention

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

	E. STATE S	SIGNATURE		
1.	Is any party described in 17 CFR 230.262 presently subject to any of the rule?	e disqualification provisions of such	Yes	No [X]
	See Appendix, Colun	nn 5, for state response.		
2.	The undersigned issuer hereby undertakes to furnish to any state admin 239.500) at such times as required by state law.	istrator of any state in which this notice is	filed, a notice on	Form D (17 CFR
3.	The undersigned issuer hereby undertakes to furnish to the state admini	strators, upon written request, information	furnished by the	e issuer to offerees.
4.	The undersigned issuer represents that the issuer is familiar with the co Exemption (ULOE) of the state in which this notice is filed and underst of establishing that these conditions have been satisfied.			
			•	
	e issuer has read this notification and knows the contents to be true and had horized person.	as duly caused this notice to be signed on	ts behalf by the u	indersigned duly
	ner (Print or Type) aya Therapeutics, Inc.	Signature	Date O 3.	122/07
	ne of Signer (Print or Type) er Cohn	Title of Signer (Print or Type) Secretary		

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed orprinted signatures.

				Al	PPENDIX	 			*
1	Intend to Sell To non- accredited investors in State (Part B-Item 1) Type of Security and aggregate offering price offered in state (Part C-Item 1)				Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E- Item I)				
State	Yes	No	Series A Preferred Stock	Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
AL ;									
AK	·								
AZ -			•						
AR				<u>-</u>					
CA		Х	\$4,000,000.00	1	\$4,000,000.00				Χ.
со									
ст									
DE									
DC					<u> </u>				
FL	<u>.</u>								
GA_				•	_				
н									
ID									
IL		<u> </u>			· L				
IN									i i
IA		<u> </u>	·		· .	, 			
KS		 							. !
KY	<u> </u>								·
LA ·						,	·		· ·
мЕ									i
MD .							·		
MA									
MI									
MN				,		-			
MS		,							
МО									
MT									'
NE					-				
NV ·									

(+ D			<u> </u>	Al	PPENDIX			· · · · · · · · · · · · · · · · · · ·			
1	2		3			5					
	Intend To n accre investors (Part B-	on- dited in State	Type of Security and aggregate offering price offered in state (Part C-Item 1)	aggregate offering Type of investor and price offered in state amount purchased in State					Disqualification under State ULOE. (if yes, attach explanation of waiver granted) (Part E- Item 1)		
State	Yes	No	Series A Preferred Stock	Number of Accredited Investors	Accredited Non-Accredited				No		
NH ·											
NJ		····				:			4		
NM						,	,		ì		
NY							,		:		
NC									7		
ND	•	•							Į.		
ОН			:			,					
ОК									1		
OR				<u>.</u>	ſ				1		
PA							٠				
RI	- -		-						4		
SC											
SD		_									
TN			٠						=		
TX									4		
UT											
V.T											
VA									. 1_		
WA											
wv									i		
WI						,					
WY											
PR											